Posted in | News

Vector Intersect Acquires Leading Provider of Security and Training Products

Vector Intersect Security Acquisition Corporation, a special purpose acquisition corporation, today announced that it has reached a definitive agreement to acquire Cyalume Light Technologies Inc., a leading provider of safety, security and training products for the US military and other militaries, for $120 million.

Under terms of the agreement, Vector will acquire Cyalume, based in West Springfield, MA, for $80.4 million in cash, which will be used to pay down Cyalume debt, and issue 4,970,765 shares to GMS Acquisition Partner Holdings, who own 100% of Cyalume. The closing of the transaction is subject to customary closing conditions, including the approval of the transaction by Vector stockholders.

Cyalume is the leading global manufacturer and supplier of chemiluminescent and infrared products sold to the military and safety markets, and is the sole supplier to the US military and government. Cyalume manufactures and sells a large scope of chemical luminescent and infrared products to defense departments, law enforcement agencies, wholesalers, retailers and distributors and retroreflective and photoluminescent materials to fire departments and safety product distributors. Cyalume sells chemical luminescent training ammunition for day and night training to the US military.

Cyalume has a very strong intellectual property position, including 21 issued patents, and is continuing to develop new products and generate additional intellectual property with several provisional and pending patents. The company successfully entered the training ammunition market in 2007 and is currently developing products that leverage its expertise and knowledge of chemical light into new applications.

The company has been able to consistently grow its top and bottom line by leveraging its intellectual property in existing and new markets. Additionally, the company has a strong focus on delivering more eco-friendly product by using biodegradable and non- hazardous chemicals.

Cyalume has a manufacturing subsidiary in Aix-en- Provence, France that provides products to European countries through a NATO contract. The long term nature of Cyalume's contracts provide stable recurring revenue and excellent visibility into their 2008 forecast. In 2008 Cyalume is forecast to generate revenues and EBITDA of $45.8 million and $14.5 million respectively. Unaudited Revenue and EBITDA for 2007 were $39.0 million and $11.3 million respectively.

Yaron Eitan, CEO of Vector stated "After ten months of searching for the right acquisition target and evaluating over thirty companies in Europe, Israel and the United States, we are excited to have selected Cyalume as our initial acquisition.

Cyalume has an excellent history of growth and profitability that we believe will continue well into the future, new product developments at the company have yielded significant success that has the potential to continue, and this transaction will provide Cyalume the ability to accelerate its growth by expanding both internationally and pursuing new market opportunities. Cyalume has a very long history of growth and profitability and a uniquely defendable position in its market."

Stephen Weinroth, Chairman of Cyalume stated "The timing of this transaction is ideal for Cyalume. We are entering a period of strong growth and the acquisition of the company by Vector will provide us the access to capital that we need to realize our full potential. Our recent success in new markets such as training ammunition is a fine example of how our chemical light technologies can be expanded into new opportunities and markets continually broadening our product scope."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.